PACS (Hospitals & clinics) Stock Valuation & Fair Value
Significantly overvaluedPACS (Hospitals & clinics) trades at a current P/E of 20.4, about 41% above its historical normal valuation, with a forward growth estimate of 9.5% and a PEG of 2.14. Analysts' one-year estimates have been hit 100% of the time. Priced at its historical normal P/E of 14.4 on the same blended earnings, the 2026-10-30 close of $47.81 corresponds to about $33.80 a share. This is a valuation reference, not a price target.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
Valuation flags
- Long-term debt is over half its capital (73%)
- Overvalued by 41%
Frequently asked questions
Is PACS overvalued?
At a current P/E of 20.4 versus its historical normal P/E of 14.4, PACS trades about 41% above its typical valuation, with a PEG of 2.14 on 9.5% forward growth. tickerseer currently rates it significantly overvalued.
What is PACS's fair value and PEG?
PACS trades at a current P/E of 20.4 against a historical normal P/E of 14.4, a PEG of 2.14, and a forward growth estimate of 9.5%. Priced at its historical normal P/E of 14.4 on the same blended earnings, the 2026-10-30 close of $47.81 corresponds to about $33.80 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of PACS changed?
tickerseer's rating has been significantly overvalued since 2026-10-31.
Industry: Hospitals & clinics. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.